(Reuters) - Seroquel is AstraZeneca's second-biggest drug, with global sales of $3.4 billion last year.
Seroquel XR is not ground-breaking, but its approval will come as a welcome boost to AstraZeneca after the recent high-profile failures of two new drugs for stroke and heart disease, which followed earlier setbacks.
Read more at Reuters.com Government Filings News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment